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Background. Efficient viral load testing is needed for hepatitis C (HCV) surveillance and diagnosis. HCV viral load testing 
using dried blood spots (DBSs), made with a single drop of finger-prick whole blood on filter paper, is a promising alternative to 
traditional serum- or plasma-based approaches.
Methods. We adapted the Abbott Molecular m2000 instrument for high-throughput HCV viremia testing using DBSs with sim-
ple specimen processing and applied these methods to estimate the national burden of infection in the Democratic Republic of the 
Congo (DRC). We tested DBSs collected during the 2013–2014 DRC Demographic and Health Survey, including 1309 adults ≥40 
years of age. HCV-positive samples underwent targeted sequencing, genotyping, and phylogenetic analyses.
Results. This high-throughput screening approach reliably identified HCV RNA extracted from DBSs prepared using whole 
blood, with a 95% limit of detection of 1196 (95% confidence interval [CI], 866–2280) IU/mL for individual 6-mm punches and 494 
(95% CI, 372–1228) IU/mL for larger 12-mm punches. Fifteen infections were identified among samples from the DRC Demographic 
and Health Survey; the weighted country-wide prevalence of HCV viremia was 0.9% (95% CI, 0.3%–1.6%) among adults ≥40 years 
of age and 0.7% (95% CI, .6%–.8%) among human immunodeficiency virus–infected subjects. All successfully genotyped cases were 
due to genotype 4 infection.
Conclusions. DBS-based HCV testing represents a useful tool for the diagnosis and surveillance of HCV viremia and can eas-
ily be incorporated into specimen referral systems. Among adults ≥40 years of age in the DRC, 100 000–200 000 may have active 
infection and be eligible for treatment.
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Recent evidence suggests that dried blood spots (DBSs) can 
be used confidently for hepatitis C (HCV) viral load testing in 
the laboratory, but they have not been field tested in large-scale 
surveys [1, 2]. DBSs are prepared with whole blood from a fin-
ger prick in the field and can be stored at room temperature 
for months with only minimal degradation of HCV RNA [3]. 
DBSs are easily incorporated into specimen referral networks 
and offer significant advantages over traditional venous blood–
based approaches, which typically require venipuncture, centri-
fugation, and a cold chain [4]. Such costly sample processing 
requirements are not feasible in large-scale surveys, especially 
in resource-limited settings.
In developing countries such as the Democratic Republic of 
the Congo (DRC), HCV infections frequently go undiagnosed 
and untreated. The burden of HCV in sub-Saharan Africa has 
not been well characterized, despite estimates indicating that the 
region harbors some of the highest viral hepatitis rates in the world 
[5]. One study of elderly inhabitants of Kinshasa found that nearly 
26% were HCV seropositive and 14% were viremic, although 
prevalence rates are likely lower in younger age groups [6].
DBSs are commonly collected in sub-Saharan Africa during 
large-scale health surveys, such as Demographic and Health 
Surveys (DHSs). More than 27 000 subjects were enrolled in 
the 2013–2014 DRC DHS, which included DBS collection from 
a nationally representative sample for the purpose of human 
immunodeficiency virus (HIV) and vaccine-related serological 
testing and malaria molecular testing [7]. However, these DBS 
samples also afforded the opportunity to delineate the extent 
and characteristics of HCV infection throughout the country.
Using DBSs, we employed a commercially available, 
high-throughput testing platform that is widely deployed in 
African reference laboratories to detect HCV viremia. We 
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subsequently performed targeted sequencing and phylogenetic 
analyses of HCV RNA extracted from these DBSs to define 
prevalent genotypes and explore their evolutionary history. Our 
results demonstrate the utility of DBS-based HCV viral load 
testing and genotyping in resource-limited settings such as the 
DRC for identifying individuals who may benefit from treat-
ment with new, highly effective direct-acting antivirals.
MATERIALS AND METHODS
Study Population
We randomly selected 25% of adults enrolled in the 2013–2014 
DRC DHS from each of the DRC’s 11 provinces who were at least 
40 years of age and provided DBS samples, with sampling strat-
ified by province. We purposefully oversampled HIV-infected 
subjects, including 50% of all HIV-infected adults who were at 
least 40 years of age. Additionally, we subsequently performed 
focused regional testing on adults from Kasai Occidental and 
Kasai Oriental Provinces, the region with highest HCV viremia 
prevalence during initial testing. Because provincial borders 
were redrawn shortly after completion of the DHS, data analysis 
was conducted using the 26 newly drawn provinces adopted 
in 2015. DBS samples were collected in the field according to 
DHS protocol, transported at room temperature to the DRC’s 
National AIDS Control Program national reference laboratory 
in Kinshasa, and stored at –80°C as individual 6-mm punches 
until further testing [8]. This study was approved by the 
Kinshasa School of Public Health and the University of North 
Carolina institutional review boards.
Validation of RNA Extraction and Hepatitis C Viral Load Testing Methods
We used mock DBSs to determine the performance char-
acteristics of the Abbott m2000 RealTime System (Abbott 
Laboratories, Abbott Park, Illinois), the mSample Preparation 
System (m2000sp) for RNA extraction, and the RealTime HCV 
Viral Load assay for quantitative reverse-transcription poly-
merase chain reaction (qRT-PCR) viral load testing. First, we 
used a HCV genotype 2 plasma sample diluted in whole blood 
to make DBSs containing target viral load concentrations of 
250 000, 25 000, 5000, 2000, 1000, 500, and 250 international 
units (IU)/mL. Seventy-microliter aliquots of each dilution 
were placed onto Whatman filter paper (GE Healthcare, Little 
Chalfont, United Kingdom) and allowed to dry at room tem-
perature overnight. Experiments to evaluate the reproducibility 
of quantitative viral load results and the assay’s limits of detec-
tion (LOD) were performed using multiple replicates.
To simulate samples available for testing through the 2013–
2014 DRC DHS, we initially tested individual 6-mm punches 
from each DBS. After the 6-mm DBS punches were incubated 
in 0.5 mL Abbott mSample Preparation System DBS Buffer at 
55°C for 30 minutes, 400 µL of eluate was transferred into the 
m2000sp reaction vessel and processed using the RealTime 
HCV 0.2 mL assay according to the manufacturer’s instructions 
for RNA extraction, amplification, and detection. In addition, 
we evaluated the assay’s performance using larger 12-mm 
punches. These larger samples were directly loaded into the 
m2000sp reaction vessel, incubated in 1.3 mL DBS buffer at 
room temperature for 30 minutes, and processed using the 
RealTime HCV 1 mL DBS HCV RNA open mode protocol 
for sample extraction, amplification, and detection. Viral load 
results obtained from the DBSs were compared to known viral 
loads in whole blood.
Field Samples: Hepatitis C Viral Load Testing and Genotyping
Individual 6-mm punches from DBSs collected during the 
DHS underwent elution, RNA extraction, and HCV qRT-
PCR as described above. For positive samples, we attempted 
genotyping after manual RNA extraction from a new 6-mm 
punch of each positive sample using TRIzol (Thermo Fisher 
Scientific, Waltham, Massachusetts) and chloroform. Each 
punch was incubated in 400 µL of TRIzol reagent for 60 min-
utes at room temperature with agitation and subsequently pro-
cessed according to the manufacturer’s instructions for RNA 
extraction. For an additional subset of samples selected from 
the Kasai region, only manual RNA extraction using leftover 
sample stored at –70°C in DBS buffer from initial viral load 
testing was attempted. For this subset, we incubated 250 µL of 
each DBS buffer sample with 750 µL of TRIzol for 5 minutes at 
room temperature with agitation, followed by RNA extraction 
according to the manufacturer’s instructions. Immediately after 
isolating RNA from the DBS punches or DBS buffer, we gen-
erated complementary DNA (cDNA) using random hexamer 
primers and SuperScript IV Reverse Transcriptase (Thermo 
Fisher Scientific) following the manufacturer’s protocol, with 
inclusion of RNaseOut. Twenty microliters of cDNA was gen-
erated for each sample and stored at –20°C prior to PCR for 
HCV gene amplification.
We then genotyped samples by characterizing the 5ʹ-un-
translated region (5ʹ-UTR), core/E1, and NS5B regions of the 
HCV genome using PCR and Sanger sequencing. These regions 
are regularly used for HCV genotyping and represent areas of 
low, medium, and high divergence between genotypes, respec-
tively [9]. Primers and reaction conditions are described in 
Supplementary Table 1. For nested PCR reactions, first-round 
products were diluted 100-fold in nuclease-free water prior to 
inclusion in second-round reactions. For samples that failed 
to amplify NS5B using 2  µL of cDNA template, assays were 
repeated using 5 µL of cDNA template. Amplicons were visu-
alized using 1% agarose gel electrophoresis prior to sequencing.
Amplicons underwent bi-directional Sanger sequencing at 
Eton Biosciences (Research Triangle Park, North Carolina). 
Raw sequence reads were first processed using Sequencher 5.4 
(Gene Codes Corporation, Ann Arbor, Michigan). Sequences 
were trimmed to yield reads in which the first and last 10 bases 
contained <1 base with confidence values <25. Contigs were 
generated by aligning forward and reverse sequences from a 
given sample and resolving discrepancies by visual inspection 
of chromatograms. Contigs were imported into MEGA 7.0, 
along with additional reference genomes downloaded from 
GenBank, for phylogenetic analysis [10, 11]. Reference genome 
phylogenies were generated using HCV coding regions only 
(aligned by codon), and sequences were aligned using MUSCLE 
[12]. Phylogenies were generated in MEGA using a general 
time reversible model with a discrete gamma distribution and 
assuming that a proportion of sites are evolutionarily invariable. 
All trees were bootstrapped 100 times. Trees were visualized in 
R (R Core Team, Vienna, Austria) using the APE package [13]. 
Accession numbers for sequences uploaded to GenBank are as 
follows: KY793121–KY793148.
Data Analysis
We used probit analysis to assess the limits of detection of 
the Abbott platform and generate confidence intervals (CIs). 
We calculated the national and provincial prevalence of HCV 
viremia using sample weights employed during the DHS to 
account for complex sampling design [14]. Logistic regression 
models were used to test hypotheses and generate Wald P val-
ues. HCV prevalence rates by province were mapped using 
ArcGIS version 10.3 (ESRI, Redlands, California) and analyzed 
for spatial clustering by DHS cluster using the Moran I statis-
tic. Statistical analyses were performed using SAS 9.4 software 
(SAS Institute, Cary, North Carolina), except for probit analysis, 
which was conducted using version 9.3.
RESULTS
Initial testing confirmed that the m2000 system can be applied 
to detect HCV infection using DBS samples. During testing of 
thirty-nine 6-mm DBS punches made using whole blood con-
taining RNA concentrations above the RealTime HCV Viral 
Load assay’s limits of quantification—250 000 (5.4 log10) IU/
mL, 25 000 (4.4 log10) IU/mL, and 5000 (3.7 log10) IU/mL of 
HCV RNA—the RealTime HCV assay quantified all DBS rep-
licates with minimal variation between replicates (mean 3.4 
log10 IU/mL, 2.6 log10 IU/mL, and 1.8 log10 IU/mL; coefficient 
of variation 1.8%, 5.8%, and 5.4%, respectively; Supplementary 
Table 2). Among these samples, quantitative viral loads from 
individual 6-mm DBS punches were 1.8–2.0 log10 lower than 
the known viral load in whole blood. Testing of 122 individual 
6-mm punches from DBSs made using whole blood containing
250–5000 (2.4–3.7 log10) IU/mL revealed a 95% LOD of 1196
(95% CI, 866–2280) IU/mL; Table 1). Subsequent testing of 139
larger 12-mm punches revealed a 95% LOD of 494 (95% CI,
372–1228) IU/mL (Table 1). Having confirmed that the assay
reliably detected HCV infections using DBSs made from whole
blood, we then applied these methods to estimate the national
and provincial prevalence of HCV viremia using DBSs collected 
during the 2013–2014 DRC DHS.
We initially selected 1015 of the 3939 adults who were at least 
40 years of age and had DBSs available for testing, including 19 
of 38 HIV-infected subjects (Figure 1). Subsequently, focused 
regional testing was also performed on 294 additional adults 
from Kasai Occidental and Kasai Oriental provinces, the region 
with highest HCV viremia prevalence during initial testing.
We identified 15 cases of HCV viremia among 1309 sub-
jects tested, representing a national weighted prevalence of 
0.9% (95% CI, .3%–1.6%) among adults 40–55  years of age 
(Table 2). HCV viremic subjects were older than HCV-negative 
subjects, but neither sex, hemoglobin level, HIV status, urban 
residence, nor wealth index were risk factors for HCV viremia. 
One case of HIV/HCV coinfection was observed, represent-
ing a 0.7% (95% CI, .6%–.8%) weighted national prevalence 
of HCV viremia among HIV-infected subjects or 4.7% of the 
21 HIV-infected subjects tested. While initial results suggested 
the possibility of geographic clustering in the central Kasai 
Orientale and Kasai Occidental provinces, analysis after test-
ing of additional samples and incorporation of sample weights 
to account for complex survey design did not reveal signifi-
cant spatial clustering (Moran I = 0.016, P = .08; Figure 2 and 
Supplementary Table 3).
We successfully genotyped 10 of the 15 subjects. The 5 sam-
ples with unknown genotype had low quantitative HCV viral 
loads (Supplementary Table 4), ranging from detectable (<1.48 
log10) to 2.76 log10 IU/mL from a single 6-mm DBS punch. As 
expected, manual TRIzol/chloroform RNA extraction directly 
from DBSs was more effective than extraction from leftover DBS 
Table 1. Limits of Detection Testing of the RealTime Hepatitis C Virus (HCV) Viral Load Assay Using RNA Extracted From Circular Punches of Mock Dried 
Blood Spots Made With Whole Blood Containing Various Target Concentrations of HCV RNA
Target Concentration, 
IU/mL Whole Blood
6-mm DBS Punch 12-mm DBS Punch
Tested, No. Detected, No. % Tested, No. Detected, No. %
5000 15 15 100 31 31 100
2000 19 19 100 16 16 100
1000 30 27 90 40 40 100
500 30 21 70 33 31 94
250 28 9 32 28 21 75
Abbreviations: DBS, dried blood spot; IU, international units.
buffer. Using manual extraction followed by 2-step RT-PCR and 
gel electrophoresis, we visualized HCV amplicons from 9 of 11 
(81.8%) DBSs and 1 of 4 (25%) leftover DBS buffer aliquots, 
a difference at least partially explained by the effect of sample 
dilution during m2000 processing.
Phylogenetic analyses confirmed that genotype 4 infections 
are most common in the DRC and revealed what may be a novel 
subtype. Genotype 4k was the most common in this cohort 
(30%), followed by 4c (20%), 4f (10%), 4l (10%), and 4r (10%). 
One sample produced contradictory genotyping results—the 5ʹ-
UTR amplicon clustered with a reference 4a sequence, whereas 
the NS5B amplicon clustered with a reference 4l. Because the 
NS5B region of HCV is more phylogenetically informative, 
we assigned it to subtype 4l but could not definitively exclude 
the possibility of intersubtype recombination [15]. Samples 2 
and 14 show high sequence homology but fail to cluster with 
any known subtype. Because there was insufficient sample for 
sequencing of their entire coding region; however, assignment 
of a new subtype designation according to recently proposed 
definitions was not possible [16].
Sequences clustered with known HCV genotype 4 subtypes 
(Figure 3), with the exception of samples 2 and 14 as described 
above. Additionally, NS5B sequences clustered with Central 
African sequences (Supplementary Figure  1), suggesting an 
autochthonous origin of genotype 4 HCV as previously pro-
posed [17].
DISCUSSION
We successfully detected and sequenced HCV RNA from DBSs 
collected during a national population-based survey, produc-
ing the first national HCV prevalence estimates from the DRC. 
Table 2. Characteristics of Adults With Hepatitis C Virus Viremia
Characteristica All Subjects HCV RNA Positive HCV RNA Negative P Value
No. 1309 15 1294 …
Prevalence, % (95% CI) … 0.9 (.3–1.6) 99.1 (98.4–99.7) …
Age, y, median (IQR) 44.9 (41.9–48.6) 49.0 (43.9–55.7) 44.9 (41.9–48.5) .02
Age strata, y, No. (%) .01
 40–44 518 (43.6) 3 (13.7) 515 (43.9)
 45–49 471 (34.7) 5 (36.2) 466 (34.7)
 50–54 174 (12.0) 2 (9.2) 172 (12.0)
 ≥55 146 (9.7) 5 (40.9) 141 (9.4)
Male sex, No. (%) 798 (60.4) 12 (74.6) 786 (60.2) .41
HIV infection, No. (% [95% CI]) 21 (1.5) 1 (1.1 [.8–1.4]) 20 (1.5 [.6–2.5]) .74
Hemoglobin,b mean, g/dL (95% CI) 13.4 13.5 (13.1–13.8) 13.4 (13.3–13.5) .88
Urban place of residence, No. (% [95% CI]) 390 (30.0) 4 (32.6 [21.2–43.9]) 386 (29.9 [25.5–34.3]) .85
Wealth index quintile, mean (95% CI)c 3.0 3.0 (2.4–3.6) 2.9 (2.8–3.1) .87
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range.
aAll summary statistics are weighted to account for complex survey design. Sample sizes are unweighted. Percentages reflect the weighted proportion of subjects (all, HCV RNA positive, 
or HCV RNA negative) with the specified characteristic.
bAltitude-adjusted.
cDemographic and Health Survey–calculated wealth index, where 1 = poorest and 5 = richest compared to other participants [25].
Figure  1. Study population and hepatitis C virus (HCV) testing results, including subsequent testing of additional samples selected from Kasai Orientale and Kasai 
Occidental provinces after initial testing. 
High-throughput sample extraction and HCV qRT-PCR using 
the Abbott m2000 system provided an efficient means of HCV 
RNA screening with limited specimen processing, requiring 
only a brief incubation followed by direct analysis of the eluate. 
In addition, we successfully genotyped two-thirds of all HCV 
viremia cases.
Figure 2. Hepatitis C virus (HCV) viremia prevalence by province, stratified by the weighted percent of the population with HCV viremia. The number in red corresponds to 
the genotype and the letters following the number correspond to the subtype. Abbreviation: U, unknown.
Figure 3. Phylogenetic analyses. Samples from the current study (red) clustered with reference sequences (black) from known genotype 4 subtypes for both the hepatitis 
C virus NS5B (A) and core/E1 (B) regions, except for samples 2 and 14. Reference sequence identifying information is separated by periods and includes the following (from 
left to right): genotype and subtype, isolate identifier, GenBank accession number.
This approach has broad utility throughout much of sub-Sa-
haran Africa, as the required laboratory infrastructure is already 
established for HIV viral load testing. By employing a similar 
workflow to what is required for ongoing HIV projects, minis-
tries of health in resource-limited settings can identify subjects 
eligible for HCV treatment. HCV RNA levels from untreated 
HCV-positive blood donors remain high and generally stable 
during longitudinal studies, indicating that the current assay’s 
limits of detection would permit identification of virtually all 
patients in need of antiviral therapy [18].
This approach allowed for the first national HCV viremia 
prevalence estimates for the DRC, indicating that 0.9% of adults 
aged 40–55 are actively viremic (95% CI, .3%–1.6%). The prev-
alence and provincial distribution of cases we observed is con-
sistent with recent serological analyses of subjects with acute 
febrile jaundice who were referred for yellow fever testing in 
the DRC [19]. The prevalence of HCV viremia was similar to 
US estimates, where infected individuals are increasingly cured 
through treatment with direct-acting antivirals [20, 21]. While 
treatment is available in select settings in Africa through dis-
counted pricing or generic licensing agreements, treatment 
remains largely unavailable in the DRC. Genotype 4 infections 
predominate in the DRC and are amenable to treatment with 
recently approved direct-acting antiviral combination regimens.
The association between older age and HCV viremia supports 
the hypothesis that HCV transmission rates were high in mid-
20th-century DRC due to iatrogenic causes, including mass treat-
ment campaigns involving injectable agents prior to the discovery 
of blood-borne viruses [6, 22]. Additionally, the predominance of 
genotype 4 and its subtypes is consistent with reports that sug-
gest an autochthonous origin in Central Africa [17]. We did not 
observe any cases of HCV genotype 7, a recently described geno-
type that may have originated in Central Africa [11].
While the comprehensive survey design of the DHS allowed 
us to estimate the prevalence of HCV viremia, additional 
research is required to refine these estimates. Specifically, prov-
inces without cases of HCV viremia should not be assumed to be 
free of HCV infections. Additionally, our genotyping methods 
maximized our ability to examine the genetic diversity of HCV 
using limited clinical samples but are not readily adapted for 
high-throughput use. We chose to use reflex TRIzol-chloroform 
RNA extraction and sequencing for phylogenetic analysis for 
2 reasons. First, TRIzol-chloroform generally outperforms 
high-throughput RNA extraction approaches, typically achiev-
ing approximately 1 log10 greater RNA concentration than col-
umn-based kits in our hands. Second, sequencing was necessary 
to permit identification of genotype 7 cases that might be missed 
by commercially available assays for routine genotyping. While 
we expect that commercially available genotyping assays could 
be applied successfully to RNA extracted using automated meth-
ods, the recent release of pan-genotypic, direct-acting antivirals 
suggests that the role of genotyping may be less important in 
pretreatment testing algorithms, particularly in resource-limited 
environments. A simplified approach that links viremic patients 
to care, irrespective of genotype, is especially appealing in set-
tings with limited laboratory capacity such as the DRC.
DBS-based testing is likely feasible using other commercially 
available HCV RNA assays using protocols optimized for this 
approach. Future studies could involve initial serological screen-
ing for HCV antibodies to reduce costs, followed by reflex RNA 
testing using an entire DBS rather than a single 6-mm punch to 
improve assay sensitivity [23]. This approach was not possible 
in the current study due to limited sample quantity. The advent 
of point-of-care HCV antibody testing could further streamline 
testing by allowing for real-time, targeted screening followed by 
reflex DBS-based RNA testing and linkage to care.
In conclusion, DBS-based viral load testing allowed us to 
determine the prevalence and characteristics of HCV viremia 
in the DRC. Based on crude 2016 population estimates, we 
expect that at least 100 000–200 000 adults ≥40  years of age 
are actively infected and eligible for treatment [24]. Without 
access to direct-acting HCV antivirals, many of these individ-
uals will suffer the devastating effects of chronic HCV infec-
tion, including cirrhosis, hepatocellular carcinoma, and death. 
High-throughput screening for HCV RNA in resource-limited 
settings can be achieved using existing laboratory infrastruc-
ture, allowing for the identification of individuals eligible for 
curative treatment.
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